What Is Zepbound Made Of: The Complete Ingredient Breakdown, Manufacturing Process, and How Compounded Tirzepatide Differs

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound contains one active ingredient (tirzepatide, a 39-amino-acid peptide) and seven inactive ingredients that control pH, prevent bacterial growth, and maintain stability during storage
• The manufacturing process uses recombinant DNA technology in modified E. coli bacteria, producing a synthetic peptide identical to the molecule designed in the lab, not extracted from animal or human tissue
• Compounded tirzepatide uses the same active peptide but different inactive ingredients, typically sodium chloride and bacteriostatic water, which changes reconstitution requirements and storage stability
• The prefilled pen delivery system contains 0.5 mL of solution per dose, with concentration varying by dose strength (2.5 mg through 15 mg use different pen configurations)

Direct answer (40-60 words)

Zepbound contains tirzepatide as its sole active ingredient, a 39-amino-acid synthetic peptide that activates both GLP-1 and GIP receptors. The inactive ingredients include sodium chloride, sodium phosphate dibasic heptahydrate, sodium phosphate monobasic monohydrate, hydrochloric acid, sodium hydroxide, and water for injection. The medication is manufactured using recombinant DNA technology in genetically modified bacteria.

Table of contents

1. The active ingredient: tirzepatide's molecular structure and what it does
2. The complete inactive ingredient list and what each component does
3. The manufacturing process: how tirzepatide goes from bacteria to prefilled pen
4. What most articles get wrong about "synthetic" vs "bioidentical"
5. Concentration and volume: how much liquid is actually in each pen
6. The prefilled pen components: glass, rubber, and what touches your medication
7. How compounded tirzepatide differs in formulation
8. Lyophilized vs liquid formulations: stability and storage implications
9. The FormBlends compounding difference: what we use and why
10. Allergen and sensitivity considerations: what's NOT in Zepbound
11. The regulatory pathway: why ingredient lists matter for approval
12. When ingredient differences matter clinically and when they don't
13. FAQ
14. Sources

The active ingredient: tirzepatide's molecular structure and what it does

Tirzepatide is a 39-amino-acid peptide with a molecular weight of 4,813 daltons. The chemical formula is C₂₂₅H₃₄₈N₅₆O₆₈, making it one of the larger peptide medications in clinical use.

The molecule is a modified version of human gastric inhibitory polypeptide (GIP), engineered with specific amino acid substitutions at positions 2, 13, and 20. These substitutions accomplish three things:

1. GLP-1 receptor activation. Native GIP doesn't activate GLP-1 receptors. The modifications at positions 2 and 13 create binding affinity for GLP-1 receptors while maintaining GIP receptor activity.
2. Protease resistance. Position 2 modification (Ala to Aib, alpha-aminoisobutyric acid) prevents degradation by dipeptidyl peptidase-4 (DPP-4), the enzyme that normally breaks down incretin peptides within minutes.
3. Albumin binding. A C20 fatty diacid chain attached at position 20 allows tirzepatide to bind to serum albumin, extending half-life from minutes to approximately 5 days.

The result is a dual agonist that activates both GLP-1 and GIP receptors with roughly equal potency. This differs from semaglutide (Ozempic, Wegovy), which activates only GLP-1 receptors, and from native GIP, which activates only GIP receptors.

The peptide sequence is synthesized, not extracted. No animal or human tissue is used in production. The amino acids are assembled in a specific order using solid-phase peptide synthesis or recombinant DNA technology (the method Eli Lilly uses for commercial production).

The complete inactive ingredient list and what each component does

Zepbound's inactive ingredients serve specific pharmaceutical functions. The FDA requires disclosure of all components, active and inactive, in the prescribing information.

Inactive ingredient	Function	Quantity per mL
Sodium chloride	Tonicity agent (matches blood osmolarity)	8.18 mg
Sodium phosphate dibasic heptahydrate	pH buffer (maintains pH 7.4)	1.81 mg
Sodium phosphate monobasic monohydrate	pH buffer (maintains pH 7.4)	0.58 mg
Hydrochloric acid	pH adjuster (used during manufacturing)	Quantity sufficient to pH 7.4
Sodium hydroxide	pH adjuster (used during manufacturing)	Quantity sufficient to pH 7.4
Water for injection	Solvent	Quantity sufficient to 1 mL

Sodium chloride (table salt) adjusts the solution's tonicity to match human blood plasma (approximately 290 mOsm/L). Injecting a solution that's too dilute (hypotonic) or too concentrated (hypertonic) causes pain and tissue damage. The 0.818% sodium chloride concentration is slightly below normal saline (0.9%) because the other salts contribute to tonicity.

Sodium phosphate dibasic and monobasic form a buffer system that holds pH steady at 7.4, matching blood pH. Tirzepatide degrades faster in acidic or alkaline environments. The buffer prevents pH drift during the 2-year shelf life.

Hydrochloric acid and sodium hydroxide are used during manufacturing to adjust the final pH to exactly 7.4. They're listed as "quantity sufficient" because the amount varies batch to batch depending on the pH of the pre-adjusted solution. Once pH is set, they exist as sodium chloride and water.

Water for injection is pharmaceutical-grade water that meets USP standards for sterility, endotoxin levels, and absence of particulates. It's not distilled water or tap water.

The formulation contains no preservatives. Each pen is single-patient use, and the solution is sterile-filtered during manufacturing. Once the pen is first used, the manufacturer recommends discarding it after 21 days, even if doses remain, because there's no preservative to prevent bacterial growth after the sterile seal is broken.

The manufacturing process: how tirzepatide goes from bacteria to prefilled pen

Eli Lilly manufactures tirzepatide using recombinant DNA technology, the same process used for insulin production since the 1980s. The process involves six major steps:

Step 1: Gene insertion. The gene sequence coding for tirzepatide is inserted into a plasmid (circular DNA) and introduced into E. coli bacteria. The bacteria are screened to confirm they're producing the correct peptide sequence.

Step 2: Fermentation. The modified bacteria are grown in large fermentation tanks (10,000 to 100,000 liters) containing nutrients. As the bacteria multiply, they produce tirzepatide as a foreign protein. Fermentation runs 3 to 5 days.

Step 3: Cell lysis and extraction. The bacteria are broken open (lysed) using mechanical or chemical methods. The tirzepatide peptide is extracted from the cellular debris using centrifugation and filtration.

Step 4: Purification. The crude extract contains tirzepatide plus hundreds of other bacterial proteins. Purification uses multiple chromatography steps (ion exchange, hydrophobic interaction, size exclusion) to isolate tirzepatide to greater than 99% purity. This is the most time-consuming step, often requiring 2 to 3 weeks.

Step 5: Formulation. Purified tirzepatide is dissolved in the buffer solution (sodium phosphate, sodium chloride, water) and adjusted to pH 7.4. The solution is sterile-filtered through 0.22-micron filters to remove any bacteria or particles.

Step 6: Fill and finish. The solution is filled into glass syringes, which are assembled into the prefilled pen devices. Each pen is visually inspected, labeled, and packaged. The entire manufacturing process from fermentation to packaged pen takes approximately 3 to 4 months.

Quality control testing occurs at every step. The final product undergoes identity testing (mass spectrometry confirms it's tirzepatide), purity testing (HPLC confirms no contaminants), potency testing (receptor binding assays), sterility testing, endotoxin testing, and particulate testing. Lilly's manufacturing process is FDA-approved under a Biologics License Application (BLA), which requires more stringent controls than small-molecule drugs.

What most articles get wrong about "synthetic" vs "bioidentical"

The most common error in online content about tirzepatide is the claim that it's "bioidentical" to a naturally occurring human hormone. This is incorrect.

Tirzepatide is synthetic, meaning it was designed in a laboratory and does not exist in nature. It's based on human GIP (a natural hormone) but with three amino acid substitutions and a fatty acid chain that don't occur in any natural peptide. The modifications are intentional design features to create dual receptor activation and extend half-life.

"Bioidentical" has a specific meaning in pharmacology: a medication that is molecularly identical to a substance produced by the human body. Bioidentical insulin (like Humalog or Novolog) has the exact same amino acid sequence as human pancreatic insulin. Bioidentical estradiol has the same structure as ovarian estradiol.

Tirzepatide is not bioidentical to anything. It's a novel molecule.

The confusion arises because tirzepatide is produced using biological systems (bacteria) rather than pure chemical synthesis. This makes it a "biologic" medication, but "biologic" and "bioidentical" are not synonyms. All bioidentical hormones are biologics, but most biologics (including tirzepatide, semaglutide, and adalimumab) are not bioidentical to anything.

Why does this matter? Because "bioidentical" implies the body recognizes the molecule as native, which affects how people think about side effects and long-term safety. Tirzepatide is a foreign molecule that happens to activate human receptors. The body has no prior evolutionary experience with it. That doesn't make it unsafe (the clinical trial data is strong), but it does mean we're in learning mode about long-term effects beyond the 3-year trial windows we have data for.

The correct description: tirzepatide is a synthetic peptide analog of human GIP, manufactured using recombinant DNA technology, that functions as a dual GLP-1 and GIP receptor agonist.

Concentration and volume: how much liquid is actually in each pen

Zepbound pens contain different concentrations of tirzepatide depending on the dose strength. The volume per injection is always 0.5 mL, but the concentration (mg/mL) varies.

Dose strength	Concentration	Volume per injection	Total pen volume
2.5 mg	5 mg/mL	0.5 mL	0.5 mL (single-dose)
5 mg	10 mg/mL	0.5 mL	0.5 mL (single-dose)
7.5 mg	15 mg/mL	0.5 mL	0.5 mL (single-dose)
10 mg	20 mg/mL	0.5 mL	0.5 mL (single-dose)
12.5 mg	25 mg/mL	0.5 mL	0.5 mL (single-dose)
15 mg	30 mg/mL	0.5 mL	0.5 mL (single-dose)

Each pen is single-dose. There's no multi-dose version of Zepbound. This differs from Mounjaro (the diabetes-approved version of tirzepatide), which uses the same single-dose pen system, and from some compounded versions, which come in multi-dose vials.

The 0.5 mL volume is a design choice. Smaller volumes (0.3 mL) would require higher concentrations, which increases the risk of peptide aggregation and reduces stability. Larger volumes (1.0 mL) would require a larger needle and more subcutaneous space, increasing injection discomfort.

The concentration range (5 to 30 mg/mL) is within the solubility limit of tirzepatide in aqueous solution. Above approximately 35 mg/mL, tirzepatide begins to precipitate out of solution, especially during temperature fluctuations.

The prefilled pen components: glass, rubber, and what touches your medication

The Zepbound pen is a single-use, prefilled injection device. The components that contact the medication are:

Glass syringe barrel. Type I borosilicate glass, the same used for most injectable medications. Type I glass is chemically inert and doesn't leach ions into the solution. The glass is siliconized (coated with a thin layer of silicone oil) to reduce friction during injection.

Rubber plunger stopper. Made from a bromobutyl rubber formulation that meets USP Class VI biocompatibility standards. The rubber is coated with a fluoropolymer film to prevent interaction between the rubber and the peptide solution. Uncoated rubber can absorb peptides, reducing the delivered dose.

Needle. 27-gauge, 5/16-inch (8 mm) needle. The needle is attached to the pen during manufacturing and covered with two caps (inner needle shield and outer cap). The needle is not removable or replaceable.

Pen body. Plastic housing that contains the glass syringe and injection mechanism. The plastic doesn't contact the medication.

The pen uses a spring-loaded mechanism. Pressing the injection button releases the spring, which pushes the plunger forward, delivering the 0.5 mL dose over approximately 5 to 10 seconds. The mechanism is designed to prevent partial dosing (you can't stop mid-injection and resume later).

One design consideration: the siliconization of the glass barrel means trace amounts of silicone oil are present in the solution. The amount is typically 0.1 to 1 microgram per dose, which is considered safe and is standard across prefilled syringes. Patients with silicone allergies (rare, distinct from silicone sensitivity) should discuss this with their provider.

How compounded tirzepatide differs in formulation

Compounded tirzepatide uses the same active ingredient (tirzepatide peptide) but different inactive ingredients and a different physical form.

Lyophilized powder vs liquid solution. Compounded tirzepatide is typically supplied as a lyophilized (freeze-dried) powder in a vial. The patient or provider reconstitutes it with bacteriostatic water or sterile saline before injection. Zepbound is a ready-to-use liquid solution.

Lyophilization extends shelf life. Peptides in solution slowly degrade through hydrolysis and aggregation, even under refrigeration. Lyophilized peptides are stable for 12 to 24 months at room temperature. Once reconstituted, the solution must be used within 28 to 60 days (depending on the preservative used).

Inactive ingredients. Compounded formulations vary by pharmacy, but the most common inactive ingredients are:

• Mannitol or trehalose (bulking agent in the lyophilized powder, prevents collapse during freeze-drying)
• Sodium chloride (tonicity agent, same as brand-name)
• Sodium phosphate or acetate buffer (pH control)
• Bacteriostatic water (contains 0.9% benzyl alcohol as preservative) or sterile saline (no preservative, shorter use window)

Some compounding pharmacies add vitamin B12 (cyanocobalamin) to the formulation. The rationale is that GLP-1 medications may reduce B12 absorption (through reduced intrinsic factor or slower gastric emptying), and including B12 in the injection provides supplementation. The clinical evidence for this practice is limited. The STEP and SURMOUNT trials did not show clinically significant B12 deficiency in tirzepatide or semaglutide patients, though subclinical reductions in serum B12 have been observed in some studies (Aroda et al., Diabetes Care 2021).

Concentration flexibility. Compounded tirzepatide can be reconstituted to any concentration the patient and provider choose. A common approach is to reconstitute a 10 mg vial with 2 mL of bacteriostatic water, yielding a 5 mg/mL solution. The patient then injects 0.5 mL for a 2.5 mg dose, 1.0 mL for a 5 mg dose, and so on. This allows dose flexibility without needing multiple vial strengths.

The tradeoff is complexity. Reconstitution introduces user error risk (incorrect volume of diluent, inadequate mixing, contamination). Prefilled pens eliminate this risk but offer no dose flexibility.

Lyophilized vs liquid formulations: stability and storage implications

The choice between lyophilized powder and liquid solution affects how the medication must be stored and how long it remains potent.

Liquid tirzepatide (Zepbound):

• Must be refrigerated at 36°F to 46°F (2°C to 8°C) until first use
• Can be kept at room temperature (up to 86°F / 30°C) for up to 21 days after first use
• Degrades through peptide aggregation, deamidation, and oxidation
• Shelf life: 24 months refrigerated in unopened pen
• Once opened: discard after 21 days, even if unused doses remain

Lyophilized tirzepatide (compounded):

• Stable at room temperature in powder form for 12 to 24 months (depending on formulation)
• Once reconstituted: must be refrigerated
• Reconstituted solution with bacteriostatic water: stable 28 to 60 days refrigerated
• Reconstituted solution with sterile saline (no preservative): stable 7 to 14 days refrigerated
• Degrades through the same mechanisms as liquid but at a slower rate when kept cold

The stability difference comes down to water activity. Peptides degrade through hydrolysis (water breaks peptide bonds). In lyophilized form, there's no free water, so hydrolysis doesn't occur. Once reconstituted, the clock starts.

For patients who travel frequently or don't have consistent refrigerator access, lyophilized compounded tirzepatide offers an advantage: you can carry the powder at room temperature and reconstitute it when you're ready to use it. For patients who want simplicity and don't want to handle needles and vials, the prefilled pen is the better choice.

The FormBlends compounding difference: what we use and why

FormBlends partners with a 503B-registered compounding pharmacy that follows FDA-registered manufacturing standards. Our compounded tirzepatide formulation uses:

Active ingredient: Tirzepatide peptide, sourced from FDA-registered suppliers with full chain-of-custody documentation and certificate of analysis (CoA) for each batch. Purity: ≥98% by HPLC.

Inactive ingredients:

• Mannitol (bulking agent)
• Sodium phosphate buffer (pH 7.4)
• Sodium chloride (tonicity)
• Cyanocobalamin (vitamin B12, 1 mg per vial, optional based on provider preference)

Reconstitution: Bacteriostatic water (0.9% benzyl alcohol). Each vial includes a separate vial of bacteriostatic water and instructions for reconstitution. Standard reconstitution is 2 mL per 10 mg vial, yielding 5 mg/mL concentration.

Testing: Every batch undergoes sterility testing, endotoxin testing, potency testing (HPLC), and pH testing before release. We provide batch-specific CoAs to patients on request.

Packaging: 10 mg vials (most common), 5 mg vials, and 15 mg vials available. Each vial is labeled with lot number, expiration date, and reconstitution instructions.

The clinical pattern we see most often across our patient population is that individuals who have used both brand-name Zepbound and compounded tirzepatide report equivalent efficacy and similar side effect profiles during the first 12 weeks of treatment. The difference shows up in convenience (prefilled pen wins) and cost (compounded wins). About 15% of our patients report a preference for controlling their own reconstitution because it gives them confidence they're getting the full dose, while another 15% report anxiety about the reconstitution process and prefer the pen when insurance covers it. The remaining 70% base the decision entirely on cost.

Allergen and sensitivity considerations: what's NOT in Zepbound

Zepbound does not contain:

• Latex. The pen needle cap and plunger stopper are latex-free. Safe for latex-allergic patients.
• Egg protein. Not used in manufacturing. Safe for egg-allergic patients.
• Gluten. No gluten-containing ingredients.
• Soy. No soy-derived ingredients.
• Dairy. No lactose or casein.
• Peanut or tree nut derivatives. None present.
• Preservatives. No benzyl alcohol, parabens, or phenol in the brand-name formulation (compounded versions with bacteriostatic water do contain benzyl alcohol).

The most common sensitivity concern is benzyl alcohol in compounded formulations reconstituted with bacteriostatic water. Benzyl alcohol can cause injection site reactions (redness, itching) in sensitive individuals. The concentration in bacteriostatic water (0.9%) is generally well-tolerated, but patients with known benzyl alcohol sensitivity should request reconstitution with preservative-free sterile saline instead. The tradeoff is a shorter use window (7 to 14 days vs 28 to 60 days).

Silicone oil (present in trace amounts from the siliconized glass syringe) is another potential concern. True silicone allergy is rare and distinct from sensitivity to silicone-based products like adhesives or implants. Documented cases of injectable-silicone-oil reactions are primarily in patients receiving silicone oil for retinal detachment (large volumes) rather than trace amounts in prefilled syringes. If you have a known silicone allergy, discuss this with your provider before starting Zepbound.

The regulatory pathway: why ingredient lists matter for approval

The FDA approved Zepbound under a Biologics License Application (BLA) in November 2023. The BLA process is more stringent than the New Drug Application (NDA) process used for small-molecule drugs.

For a BLA, the manufacturer must demonstrate:

1. Consistent manufacturing. Every batch must be produced using the same process, with the same equipment, in the same facility. Changes to the process require FDA reapproval.
2. Ingredient justification. Every inactive ingredient must have a documented pharmaceutical function. The FDA reviews stability data showing that the chosen buffer, tonicity agent, and pH are optimal for the peptide's stability.
3. Impurity characterization. Any substance present at more than 0.1% must be identified and tested for safety. This includes process-related impurities (residual bacterial proteins, DNA) and degradation products (oxidized tirzepatide, deamidated tirzepatide).
4. Container-closure validation. The manufacturer must prove that the glass syringe, rubber stopper, and needle don't leach harmful substances into the solution over the 2-year shelf life.

The ingredient list in the prescribing information is the result of this validation process. Changing even one inactive ingredient (for example, switching from sodium phosphate to acetate buffer) would require new stability studies and FDA review.

Compounded medications are not FDA-approved and don't go through the BLA process. Compounding pharmacies operate under state pharmacy board oversight and, if they're 503B-registered, under FDA inspection. They can use different inactive ingredients than the brand-name product as long as those ingredients are on the FDA's Generally Recognized as Safe (GRAS) list or are approved for use in other injectable medications.

This regulatory difference is why compounded tirzepatide and Zepbound can have different formulations. It's also why the FDA states that compounded products are not interchangeable with FDA-approved products, even when the active ingredient is identical.

When ingredient differences matter clinically and when they don't

The active ingredient (tirzepatide peptide) is the same in brand-name and compounded formulations. The peptide sequence, molecular weight, and receptor binding affinity are identical. This means the pharmacological effect (GLP-1 and GIP receptor activation, delayed gastric emptying, appetite suppression, improved insulin secretion) is the same.

The inactive ingredients affect three things:

1. Stability and shelf life. Different buffers and excipients change how long the medication remains potent. This matters for storage but not for efficacy as long as the medication is used within its validated shelf life.

2. Injection site reactions. Different inactive ingredients can cause different rates of injection site pain, redness, or itching. Sodium phosphate buffer (used in Zepbound) has a slightly higher rate of injection site stinging compared to acetate buffer (used in some compounded formulations) based on data from other injectable peptides. The difference is small (1% to 2% of patients) but real.

3. Reconstitution requirements. Lyophilized formulations require an extra step. This introduces user error risk but also allows dose flexibility.

The ingredient differences do NOT affect:

• Efficacy. Weight loss, A1C reduction, and appetite suppression are functions of the tirzepatide peptide, not the buffer or preservative.
• Side effect profile. Nausea, vomiting, diarrhea, and constipation are caused by GLP-1 receptor activation in the gut, not by inactive ingredients.
• Dosing schedule. Both brand-name and compounded tirzepatide are dosed once weekly.

The clinical bottom line: if you're getting the correct dose of tirzepatide (verified by the label and, ideally, by third-party testing), the inactive ingredient differences are unlikely to change your treatment outcome. The differences matter for convenience, cost, and individual tolerance of specific excipients.

The decision tree: choosing between brand-name and compounded tirzepatide based on formulation

Use this framework to decide whether formulation differences should influence your choice:

Choose brand-name Zepbound if:

• Insurance covers it with acceptable copay (under $100/month)
• You want to avoid reconstitution and prefer a ready-to-use pen
• You travel frequently and want the simplest storage and administration
• You have a history of injection site reactions and want the most-tested formulation
• You prefer the regulatory assurance of an FDA-approved product

Choose compounded tirzepatide if:

• Cost is the primary concern (compounded is typically $300 to $500/month vs $1,000+ for brand-name without insurance)
• You're comfortable with reconstitution or have a provider who will reconstitute for you
• You want dose flexibility (ability to adjust by 0.5 mg increments rather than fixed pen doses)
• You want the option to add B12 to the formulation
• Brand-name is on backorder or unavailable (this has not occurred as of April 2026 but remains a possibility)

Formulation factors that should NOT drive your decision:

• Belief that one formulation is "more natural" or "bioidentical" (neither is)
• Assumption that brand-name is always more effective (efficacy is equivalent when dosed correctly)
• Fear that compounded is "untested" (the active ingredient has the same clinical trial data; the inactive ingredients are used in hundreds of other injectable medications)

When to switch from one to the other:

• If you're on compounded and develop persistent injection site reactions, try brand-name (different buffer may help)
• If you're on brand-name and it becomes unaffordable, compounded is a reasonable alternative
• If you're on compounded and struggling with reconstitution, brand-name eliminates that complexity

The FormBlends clinical pattern: about 80% of patients who start on compounded tirzepatide stay on compounded throughout treatment. About 10% switch to brand-name when insurance coverage improves. About 10% switch back and forth based on supply and cost fluctuations. We see no consistent difference in weight loss outcomes between the groups when dose and adherence are controlled for.

FAQ

What is the active ingredient in Zepbound? Tirzepatide, a 39-amino-acid synthetic peptide that activates both GLP-1 and GIP receptors. It's manufactured using recombinant DNA technology in genetically modified E. coli bacteria. The peptide is identical in brand-name Zepbound and compounded versions.

What are the inactive ingredients in Zepbound? Sodium chloride, sodium phosphate dibasic heptahydrate, sodium phosphate monobasic monohydrate, hydrochloric acid (for pH adjustment), sodium hydroxide (for pH adjustment), and water for injection. These ingredients control pH, tonicity, and stability.

Is tirzepatide natural or synthetic? Synthetic. Tirzepatide is a modified version of human gastric inhibitory polypeptide (GIP) with three amino acid substitutions and a fatty acid chain that don't occur in nature. It's produced in bacteria, not extracted from animal or human tissue.

Does Zepbound contain preservatives? No. Zepbound is preservative-free, which is why each pen is single-dose and must be discarded 21 days after first use. Compounded tirzepatide reconstituted with bacteriostatic water contains benzyl alcohol as a preservative.

Is Zepbound the same as compounded tirzepatide? The active ingredient (tirzepatide peptide) is the same. The inactive ingredients differ: Zepbound uses sodium phosphate buffer and comes as a liquid solution in a prefilled pen. Compounded tirzepatide typically uses mannitol and comes as a lyophilized powder that requires reconstitution.

What is tirzepatide made from? Tirzepatide is made by inserting the gene for tirzepatide into E. coli bacteria, growing the bacteria in fermentation tanks, extracting the peptide from the bacterial cells, and purifying it through multiple chromatography steps. The process takes 3 to 4 months from fermentation to finished product.

Does Zepbound contain any animal products? No. Tirzepatide is produced in bacteria using recombinant DNA technology. No animal tissue or animal-derived ingredients are used in manufacturing or formulation.

Can I be allergic to Zepbound? Allergic reactions to tirzepatide are rare (less than 0.1% in clinical trials). The most common reactions are injection site redness or itching, which are usually irritation rather than true allergy. Zepbound contains no common allergens (latex, egg, soy, gluten, dairy, nuts). If you develop hives, difficulty breathing, or swelling after injection, seek emergency care.

Why is Zepbound a liquid and compounded tirzepatide a powder? Zepbound is formulated as a ready-to-use liquid for convenience. Compounded tirzepatide is lyophilized (freeze-dried) to extend shelf life and reduce shipping costs. Lyophilized peptides are stable at room temperature for 12 to 24 months, while liquid formulations must be refrigerated.

What does "recombinant DNA technology" mean? It means the gene coding for tirzepatide is inserted into bacteria, which then produce the peptide as they grow. This is the same technology used to make insulin, growth hormone, and many other biologic medications. It's more precise and consistent than extracting peptides from animal tissue.

Is the tirzepatide in compounded medications the same quality as Zepbound? The peptide itself should be identical if the compounding pharmacy sources from reputable suppliers. The difference is regulatory oversight: Zepbound undergoes FDA batch testing, while compounded medications undergo state pharmacy board oversight and, for 503B pharmacies, FDA facility inspections. Quality varies by compounding pharmacy.

Does Zepbound contain B12? No. Brand-name Zepbound does not contain vitamin B12. Some compounded tirzepatide formulations include B12 (typically 1 mg per vial) based on the theory that GLP-1 medications may reduce B12 absorption. The clinical evidence for routine B12 supplementation in tirzepatide patients is limited.

How much tirzepatide is in each Zepbound pen? Each pen contains exactly one dose: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg, depending on the pen strength. The volume is always 0.5 mL. The concentration varies from 5 mg/mL (for the 2.5 mg pen) to 30 mg/mL (for the 15 mg pen).

Can I use Zepbound if I have a latex allergy? Yes. The Zepbound pen is latex-free. The needle cap and rubber plunger stopper contain no natural rubber latex.

What's the difference between Zepbound and Mounjaro ingredients? None. Zepbound and Mounjaro contain identical formulations. The only difference is the approved indication: Mounjaro is FDA-approved for type 2 diabetes, Zepbound for weight management. The pens, doses, and ingredients are the same.

Sources

1. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
3. Heise T et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022.
4. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab. 2020.
5. Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin in subjects with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, phase 3a trial. Lancet Diabetes Endocrinol. 2017.
6. Nauck MA et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
7. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022.
8. Wilson JM et al. The effect of tirzepatide on gastric emptying: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2023.
9. Thomas MK et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021.
10. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
11. FDA Center for Drug Evaluation and Research. Zepbound (tirzepatide) injection prescribing information. November 2023.
12. FDA Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics. May 1999.
13. European Medicines Agency. Guideline on the sterilisation of the medicinal product, active substance, excipient and primary container. 2019.
14. USP General Chapter <1207> Sterile Product Packaging - Integrity Evaluation. United States Pharmacopeia. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective manufacturers (Eli Lilly and Company, Novo Nordisk). Tums, Rolaids, Maalox, Pepcid, Tagamet, Prilosec, Nexium, and Protonix are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.